The single-dose coronavirus vaccine, produced by Johnson & Johnson, is 90% effective against the Delta variant of Covid-19, according to a study published Saturday by the University of Alabama at Birmingham (UAB).
“The message is that the J&J vaccine is causing really good, really long-term immunity, at least for now. It seems to be about 90% effective against the Delta variant, much like the effectiveness of RNA vaccines,” said Dr. Jean Marazzo, director of Department of Infectious Diseases at UAB.
Marazzo added that there is currently insufficient information to show whether a booster (additional) dose of the vaccine is needed.
“Theoretically, and at least in clinical cases, it seems like a good idea. As far as we know, there is no disadvantage to such a booster dose, apart from the inconvenience, side effects and, of course, the price if you pay for the vaccine. But it can have potential benefits.”
However, she declined to recommend a booster injection in light of vaccination inequalities around the world.
–
:quality(90)/cloudfront-us-east-1.images.arcpublishing.com/lanacionpy/MUOGZ6KUTRBUPH3KBLY6J3DCPI.png "Government bets on Sequera to encourage vaccination")
